Wade Iams, MD

Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.

Panelists discuss how small cell lung cancer (SCLC) differs from non–small cell lung cancer in terms of staging, epidemiology, risk factors, prevention strategies, and prognosis, while also exploring the distinctions between limited-stage and extensive-stage SCLC and considering potential improvements in staging practices.

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.

A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.